Literature DB >> 16082267

Pharmacological enhancement of aural habilitation in adult cochlear implant users.

Emily A Tobey1, Michael D Devous, Kristi Buckley, Gary Overson, Thomas Harris, Wendy Ringe, Julie Martinez-Verhoff.   

Abstract

OBJECTIVE: The purpose of this report was to examine the preliminary data collected under a larger on-going feasibility study conducted with cochlear implant patients exploring the potential benefit of pharmacologically-enhanced aural rehabilitation therapy as a means of increasing speech tracking skills.
DESIGN: Eight adult cochlear implant participants participated in a randomized, double-blind study and received either 10 mg d-amphetamine (Treatment group, N = 4) or a placebo (Placebo group, N = 4) 60 minutes prior to a 1.5 hour intensive aural rehabilitation session occurring twice a week for two months. Treatment consisted of a multi-step rehabilitation program individualized for each participant to develop auditory-only speech tracking skills. Prior to and at the conclusion of the therapy sessions, SPECT rCBF imaging and speech tracking assessments were conducted.
RESULTS: Speech tracking scores of the placebo and treatment groups were similar before the aural habilitation intervention. In the placebo group, speech tracking performance increased 13.5% for visual plus auditory and auditory only presentations as a function of aural habilitation alone. The 10 mg d-amphetamine-facilitated program resulted in minimal increases in visual plus auditory tracking scores (2%) but led to a 43% increase for auditory-only speech tracking. Regional cerebral blood flow measures indicated no substantial improvement of brain activation in the placebo group while both the extent and magnitude of primary and associative auditory cortex activations increased significantly with the pharmacologically enhanced treatment program.
CONCLUSIONS: These data support previous studies indicating an accelerated acquisition of speech and language abilities in stroke patients receiving traditional speech therapy in combination with d-amphetamine. Data, however, are preliminary and further study is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082267     DOI: 10.1097/00003446-200508001-00007

Source DB:  PubMed          Journal:  Ear Hear        ISSN: 0196-0202            Impact factor:   3.570


  7 in total

Review 1.  Technologic advances in aural rehabilitation: applications and innovative methods of service delivery.

Authors:  Robert W Sweetow; Jennifer Henderson Sabes
Journal:  Trends Amplif       Date:  2007-06

Review 2.  Cochlear implants matching the prosthesis to the brain and facilitating desired plastic changes in brain function.

Authors:  Blake S Wilson; Michael F Dorman; Marty G Woldorff; Debara L Tucci
Journal:  Prog Brain Res       Date:  2011       Impact factor: 2.453

3.  Pairing Speech Sounds With Vagus Nerve Stimulation Drives Stimulus-specific Cortical Plasticity.

Authors:  Crystal T Engineer; Navzer D Engineer; Jonathan R Riley; Jonathan D Seale; Michael P Kilgard
Journal:  Brain Stimul       Date:  2015-01-26       Impact factor: 8.955

4.  [Hearing training, hearing therapy and auditory rehabilitation in hearing impaired individuals during the last few centuries].

Authors:  M Ptok; S Meyer; A Ptok
Journal:  HNO       Date:  2012-10       Impact factor: 1.284

5.  Norepinephrine homogeneously inhibits alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate- (AMPAR-) mediated currents in all layers of the temporal cortex of the rat.

Authors:  Lu Dinh; Tram Nguyen; Humberto Salgado; Marco Atzori
Journal:  Neurochem Res       Date:  2009-04-09       Impact factor: 3.996

Review 6.  Audiologic management of older adults with hearing loss and compromised cognitive/psychoacoustic auditory processing capabilities.

Authors:  Patricia B Kricos
Journal:  Trends Amplif       Date:  2006-03

7.  Effects of L-dopa during auditory instrumental learning in humans.

Authors:  Tina Weis; Sebastian Puschmann; Andre Brechmann; Christiane M Thiel
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.